A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis

Trial Profile

A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs Ceftolozane/tazobactam (Primary) ; Meropenem
  • Indications Pyelonephritis; Urinary tract infections
  • Focus Adverse reactions
  • Acronyms MK-7625A-034
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 05 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 28 Jan 2018 Planned initiation date changed from 31 Jan 2018 to 8 Mar 2018.
    • 18 Oct 2017 Planned initiation date changed from 18 Jan 2018 to 31 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top